Nov 8 (Reuters) - Valeant Pharmaceuticals International Inc
reported a smaller-than-expected quarterly profit due
to faltering sales of its dermatology products and irritable
bowel syndrome drug, and the company cut its full-year profit
and revenue forecasts.
Read more
No comments:
Post a Comment